Viking's Weight-Loss Pill Data Disappoints, Shares Sink

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to...

Viking Therapeutics Crashes Over 40% After Weight-Loss Drug Trial Sparks Safety Concerns

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering in 2015. The rout followed the release of Phase 2 VENTURE-Oral trial results for its much-hyped weight-loss drug VK2735, an oral GLP-1/GIP receptor agonist. While the pill achieved double-digit weight loss, investor confidence was rocked by safety c…

Viking Therapeutics shares fall 40% on disappointing obesity pill trial data - Daily news Update

Shares of Viking Therapeutics plunged Tuesday after the company released midstage trial data on its obesity pill that disappointed investors.  The biotech company’s stock price dropped to about $23.80 as of Tuesday morning, from $42.09 at Monday’s close, a roughly 43% plunge. Viking’s market cap now sits at about $2.69 billion, down from more than $4 billion on Monday. The results could be a blow to Viking, which was once seen as a hot M&A targe…

Viking's Weight-loss Pill Data Disappoints, Shares Sink

Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a mid-stage trial, missing Wall Street's top-end...